|
US6100024A
(en)
|
1991-02-08 |
2000-08-08 |
Promega Corporation |
Methods and compositions for nucleic acid detection by target extension and probe amplification
|
|
US5298422A
(en)
|
1991-11-06 |
1994-03-29 |
Baylor College Of Medicine |
Myogenic vector systems
|
|
US5256555A
(en)
|
1991-12-20 |
1993-10-26 |
Ambion, Inc. |
Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
|
|
US5605798A
(en)
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
|
AU7839594A
(en)
|
1993-09-20 |
1995-04-10 |
Regents Of The University Of Colorado, The |
Strategy for the production of rna from immobilized templates
|
|
US6096503A
(en)
|
1993-11-12 |
2000-08-01 |
The Scripps Research Institute |
Method for simultaneous identification of differentially expresses mRNAs and measurement of relative concentrations
|
|
FR2733762B1
(fr)
|
1995-05-02 |
1997-08-01 |
Genset Sa |
Methode de couplage specifique de la coiffe de l'extremite 5' d'un fragment d'arnm et preparation d'arnm et d'adnc complet
|
|
US6251665B1
(en)
|
1997-02-07 |
2001-06-26 |
Cem Cezayirli |
Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
|
|
WO2001025488A2
(en)
|
1999-10-06 |
2001-04-12 |
Quark Biotech, Inc. |
Method for enrichment of natural antisense messenger rna
|
|
WO2002044196A1
(en)
|
2000-11-28 |
2002-06-06 |
University Of Massachusetts |
Methods and reagents for introducing a sulfhydryl group into the 5'-terminus of rna
|
|
AU2002230997A1
(en)
*
|
2000-12-15 |
2002-06-24 |
Genetics Institute, Llc |
Methods and compositions for diagnosing and treating rheumatoid arthritis
|
|
US8426194B2
(en)
|
2003-01-21 |
2013-04-23 |
Ptc Therapeutics, Inc. |
Methods and agents for screening for compounds capable of modulating VEGF expression
|
|
GB0316089D0
(en)
|
2003-07-09 |
2003-08-13 |
Xo Bioscience Ltd |
Differentiation method
|
|
US20140142290A1
(en)
|
2003-08-01 |
2014-05-22 |
Life Technologies Corporation |
Compositions and methods for preparing short rna molecules and other nucleicacids
|
|
EP2311994A1
(en)
*
|
2003-08-01 |
2011-04-20 |
Life Technologies Corporation |
Compositions and methods for preparing short RNA molecules and other nucleic acids
|
|
US20050287539A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Emmanuel Labourier |
Methods and compositions for preparing capped RNA
|
|
WO2007014363A2
(en)
|
2005-07-27 |
2007-02-01 |
Genentech, Inc. |
Vectors for inducible expression of hairpin rna and use thereof
|
|
RS63964B1
(sr)
|
2005-08-23 |
2023-03-31 |
Univ Pennsylvania |
Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
|
|
US9012219B2
(en)
*
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
|
US20070281336A1
(en)
|
2006-04-14 |
2007-12-06 |
Epicentre Technologies |
Kits and methods for generating 5' capped RNA
|
|
EP2104739B1
(en)
|
2006-12-21 |
2013-06-19 |
Novozymes Inc. |
Modified messenger rna stabilizing sequences for expressing genes in bacterial cells
|
|
DE102006061015A1
(de)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
|
|
WO2009046738A1
(en)
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
|
|
WO2011005799A2
(en)
|
2009-07-06 |
2011-01-13 |
Novartis Ag |
Self replicating rna molecules and uses thereof
|
|
SI3112467T1
(en)
|
2009-12-07 |
2018-06-29 |
The Trustees Of The University Of Pennsylvania |
Rna preparations comprising purified modified rna for reprogramming cells
|
|
JP2013531634A
(ja)
|
2010-05-24 |
2013-08-08 |
メルク・シャープ・エンド・ドーム・コーポレイション |
オリゴヌクレオチド送達のための新規なアミノアルコールカチオン性脂質
|
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2012038450A1
(en)
|
2010-09-21 |
2012-03-29 |
Riboxx Gmbh |
Microwave-driven rna polymerization by rna polymerases of caliciviruses
|
|
DK4108671T3
(da)
|
2010-10-01 |
2025-01-06 |
Modernatx Inc |
Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
|
|
CN103403181B
(zh)
|
2010-11-19 |
2016-09-07 |
密执安大学评议会 |
ncRNA及其用途
|
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
|
CA2835428A1
(en)
|
2011-05-17 |
2012-11-22 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof for non-human vertebrates
|
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
WO2013130161A1
(en)
|
2011-12-14 |
2013-09-06 |
modeRNA Therapeutics |
Methods of responding to a biothreat
|
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
CA2859691A1
(en)
|
2011-12-21 |
2013-06-27 |
Moderna Therapeutics, Inc. |
Methods of increasing the viability or longevity of an organ or organ explant
|
|
EP3421601B1
(en)
|
2011-12-30 |
2019-12-04 |
Cellscript, Llc |
Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
|
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
EP2834259A4
(en)
|
2012-04-02 |
2016-08-24 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2014028429A2
(en)
|
2012-08-14 |
2014-02-20 |
Moderna Therapeutics, Inc. |
Enzymes and polymerases for the synthesis of rna
|
|
US9597380B2
(en)
|
2012-11-26 |
2017-03-21 |
Modernatx, Inc. |
Terminally modified RNA
|
|
US20150315541A1
(en)
|
2012-12-13 |
2015-11-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for altering cell phenotype
|
|
EP2931319B1
(en)
|
2012-12-13 |
2019-08-21 |
ModernaTX, Inc. |
Modified nucleic acid molecules and uses thereof
|
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2014152659A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Quantitative assessment for cap efficiency of messenger rna
|
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
|
WO2014160243A1
(en)
|
2013-03-14 |
2014-10-02 |
The Trustees Of The University Of Pennsylvania |
Purification and purity assessment of rna molecules synthesized with modified nucleosides
|
|
US20160017313A1
(en)
|
2013-03-15 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Analysis of mrna heterogeneity and stability
|
|
US20160032273A1
(en)
|
2013-03-15 |
2016-02-04 |
Moderna Therapeutics, Inc. |
Characterization of mrna molecules
|
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
|
US11155572B2
(en)
|
2013-03-15 |
2021-10-26 |
Glaxosmithkline Biologicals Sa |
RNA purification methods
|
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
EP3578663A1
(en)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
|
US11377470B2
(en)
|
2013-03-15 |
2022-07-05 |
Modernatx, Inc. |
Ribonucleic acid purification
|
|
DK3019619T3
(da)
|
2013-07-11 |
2021-10-11 |
Modernatx Inc |
Sammensætninger, der omfatter syntetiske polynukleotider, som koder for crispr-beslægtede proteiner, og syntetiske sgrna'er, og anvendelsesfremgangsmåder
|
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
|
AU2014337156A1
(en)
|
2013-10-18 |
2016-05-12 |
Modernatx, Inc. |
Compositions and methods for tolerizing cellular systems
|
|
EP3076994A4
(en)
|
2013-12-06 |
2017-06-07 |
Modernatx, Inc. |
Targeted adaptive vaccines
|
|
AU2015231031A1
(en)
|
2014-03-20 |
2016-09-22 |
The Board Of Regents Of The University Of Texas System |
T7 RNA polymerase variants with expanded substrate range and enhanced transcriptional yield
|
|
RU2021109685A
(ru)
|
2014-04-23 |
2021-04-13 |
МОДЕРНАТиЭкс, ИНК. |
Вакцины на основе нуклеиновых кислот
|
|
SG11201608605QA
(en)
|
2014-06-10 |
2016-12-29 |
Curevac Ag |
Methods and means for enhancing rna production
|
|
US10286086B2
(en)
|
2014-06-19 |
2019-05-14 |
Modernatx, Inc. |
Alternative nucleic acid molecules and uses thereof
|
|
EP3169693B1
(en)
|
2014-07-16 |
2022-03-09 |
ModernaTX, Inc. |
Chimeric polynucleotides
|
|
JP2017523777A
(ja)
|
2014-07-17 |
2017-08-24 |
モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． |
ポリヌクレオチドの末端修飾
|
|
US20180000953A1
(en)
|
2015-01-21 |
2018-01-04 |
Moderna Therapeutics, Inc. |
Lipid nanoparticle compositions
|
|
WO2016164762A1
(en)
|
2015-04-08 |
2016-10-13 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
US20180208957A1
(en)
|
2015-04-30 |
2018-07-26 |
Curevac Ag |
Method for in vitro transcription using an immobilized restriction enzyme
|
|
EP3307305A4
(en)
|
2015-06-10 |
2019-05-22 |
Modernatx, Inc. |
TARGETED ADAPTIVE VACCINES
|
|
WO2017011773A2
(en)
|
2015-07-15 |
2017-01-19 |
Modernatx, Inc. |
Codon-optimized nucleic acids encoding antibodies
|
|
WO2017015457A1
(en)
|
2015-07-21 |
2017-01-26 |
Modernatx, Inc. |
Ebola vaccine
|
|
EP4218805A1
(en)
|
2015-07-21 |
2023-08-02 |
ModernaTX, Inc. |
Infectious disease vaccines
|
|
EP3328394A4
(en)
|
2015-07-30 |
2019-03-13 |
ModernaTX, Inc. |
CONCATEMEE peptide epitope RNAs
|
|
US20190008887A1
(en)
|
2015-07-30 |
2019-01-10 |
ModernaTX Inc. |
Multimeric mrna
|
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
|
WO2017031241A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Rna mapping/fingerprinting
|
|
EP3350157B1
(en)
|
2015-09-17 |
2022-01-05 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
AU2016336344A1
(en)
|
2015-10-05 |
2018-04-19 |
Modernatx, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
|
WO2017066789A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Mrna cap analogs with modified sugar
|
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
|
JP7687767B2
(ja)
|
2015-10-22 |
2025-06-03 |
モデルナティエックス インコーポレイテッド |
呼吸器合胞体ウイルスワクチン
|
|
JP6925688B2
(ja)
|
2015-10-22 |
2021-08-25 |
モデルナティーエックス， インコーポレイテッド |
水痘帯状疱疹ウイルス（ｖｚｖ）のための核酸ワクチン
|
|
BR112018008090A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacina de vírus do herpes simplex.
|
|
CA3002819A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Sexually transmitted disease vaccines
|
|
CA3002922A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
MA47016A
(fr)
|
2015-10-22 |
2018-08-29 |
Modernatx Inc |
Vaccins contre les virus respiratoires
|
|
CA3003103A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
CA3003090A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Cancer vaccines
|
|
ES2924407T3
(es)
|
2015-12-10 |
2022-10-06 |
Modernatx Inc |
Composiciones y procedimientos para el suministro de agentes terapéuticos
|
|
WO2017106799A1
(en)
|
2015-12-17 |
2017-06-22 |
Modernatx, Inc. |
POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE
|
|
SI3394030T1
(sl)
|
2015-12-22 |
2022-04-29 |
Modernatx, Inc. |
Sestave za doziranje sredstev v celice
|
|
US10465190B1
(en)
|
2015-12-23 |
2019-11-05 |
Modernatx, Inc. |
In vitro transcription methods and constructs
|
|
CN108779446B
(zh)
|
2016-01-13 |
2023-04-21 |
新英格兰生物实验室公司 |
T7 rna聚合酶的热稳定变体
|
|
EP3405579A1
(en)
|
2016-01-22 |
2018-11-28 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
|
MA45052A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille
|
|
EP3458108A4
(en)
|
2016-05-18 |
2020-04-22 |
ModernaTX, Inc. |
POLYNUCLEOTIDES ENCODING A CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS
|
|
WO2017201317A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polyribonucleotides containing reduced uracil content and uses thereof
|
|
KR102533456B1
(ko)
|
2016-05-18 |
2023-05-17 |
모더나티엑스, 인크. |
릴랙신을 인코딩하는 폴리뉴클레오타이드
|
|
CA3024507A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
|
|
EP3458081A1
(en)
|
2016-05-18 |
2019-03-27 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of citrullinemia type 2
|
|
MA45037A
(fr)
|
2016-05-18 |
2019-03-27 |
Modernatx Inc |
Polythérapie à base d'arnm pour le traitement du cancer
|
|
US20200085916A1
(en)
|
2016-05-18 |
2020-03-19 |
Modernatx, Inc. |
Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
|
|
US20190298657A1
(en)
|
2016-05-18 |
2019-10-03 |
Modernatx, Inc. |
Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
|
|
ES2973443T3
(es)
|
2016-05-18 |
2024-06-20 |
Modernatx Inc |
Polinucleótidos que codifican galactosa-1-fosfato uridililtransferasa para el tratamiento de galactosemia de tipo 1
|
|
EP3458106A4
(en)
|
2016-05-18 |
2020-03-18 |
Modernatx, Inc. |
POLYNUCLEOTIDS FOR CODING LIPOPROTEIN LIPASE FOR TREATING HYPERLIPIDEMIA
|
|
EP3458083B1
(en)
|
2016-05-18 |
2022-11-02 |
ModernaTX, Inc. |
Polynucleotides encoding interleukin-12 (il12) and uses thereof
|
|
US20200069599A1
(en)
|
2016-06-14 |
2020-03-05 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
CN106244608B
(zh)
|
2016-08-08 |
2019-10-25 |
中国科学技术大学 |
诱导的t7 rna聚合酶
|
|
CA3036831A1
(en)
|
2016-09-14 |
2018-03-22 |
Modernatx, Inc. |
High purity rna compositions and methods for preparation thereof
|
|
CA3041307A1
(en)
|
2016-10-21 |
2018-04-26 |
Giuseppe Ciaramella |
Human cytomegalovirus vaccine
|
|
MA46643A
(fr)
|
2016-10-26 |
2019-09-04 |
Modernatx Inc |
Méthodes et compositions pour le mappage d'arn
|
|
SG11201903674YA
(en)
|
2016-10-26 |
2019-05-30 |
Modernatx Inc |
Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
|
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
US10925958B2
(en)
|
2016-11-11 |
2021-02-23 |
Modernatx, Inc. |
Influenza vaccine
|
|
MA50335A
(fr)
|
2016-12-08 |
2020-08-19 |
Modernatx Inc |
Vaccins à acide nucléique contre des virus respiratoires
|
|
EP3555289A1
(en)
|
2016-12-13 |
2019-10-23 |
ModernaTX, Inc. |
Rna affinity purification
|
|
US20180243225A1
(en)
|
2017-01-25 |
2018-08-30 |
Modernatx, Inc. |
Ebola/marburg vaccines
|
|
WO2018144775A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
|
EP3577221A4
(en)
|
2017-02-01 |
2020-12-23 |
ModernaTX, Inc. |
Polynucleotide secondary structure
|
|
AU2017397458B2
(en)
|
2017-02-01 |
2025-07-10 |
Modernatx, Inc. |
RNA cancer vaccines
|
|
WO2018151816A1
(en)
|
2017-02-16 |
2018-08-23 |
Modernatx, Inc. |
High potency immunogenic compositions
|
|
WO2018157009A1
(en)
|
2017-02-24 |
2018-08-30 |
Modernatx, Inc. |
Nucleic acid-based therapy of muscular dystrophies
|
|
FI3596041T3
(fi)
|
2017-03-15 |
2023-01-31 |
|
Yhdiste ja koostumuksia terapeuttisten aineiden antamiseen solun sisään
|
|
WO2018170260A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
|
JP7332478B2
(ja)
|
2017-03-15 |
2023-08-23 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子製剤
|
|
WO2018170245A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
|
US11045540B2
(en)
|
2017-03-15 |
2021-06-29 |
Modernatx, Inc. |
Varicella zoster virus (VZV) vaccine
|
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
|
EP3595676A4
(en)
|
2017-03-17 |
2021-05-05 |
Modernatx, Inc. |
RNA VACCINES AGAINST ZOONOSES
|
|
WO2018175783A1
(en)
|
2017-03-22 |
2018-09-27 |
Modernatx, Inc. |
Rna bacterial vaccines
|
|
EP3607074A4
(en)
|
2017-04-05 |
2021-07-07 |
Modernatx, Inc. |
REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
|
|
US20200054737A1
(en)
|
2017-04-26 |
2020-02-20 |
Modema TX, Inc. |
Herpes simplex virus vaccine
|
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
|
WO2018232355A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna antibodies
|
|
KR102773542B1
(ko)
|
2017-06-30 |
2025-02-25 |
코덱시스, 인코포레이티드 |
T7 rna 폴리머라제 변이체
|
|
EP3655040A1
(en)
|
2017-07-21 |
2020-05-27 |
Modernatx, Inc. |
Modified mrna encoding a propionyl-coa carboxylase and uses thereof
|
|
ES2983060T3
(es)
|
2017-08-18 |
2024-10-21 |
Modernatx Inc |
Variantes de ARN polimerasa
|
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
|
EP3668979A4
(en)
|
2017-08-18 |
2021-06-02 |
Modernatx, Inc. |
METHOD OF HPLC ANALYSIS
|
|
MA49914A
(fr)
|
2017-08-18 |
2021-04-21 |
Modernatx Inc |
Procédés analytiques par hplc
|
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
|
MA50253A
(fr)
|
2017-09-14 |
2020-07-22 |
Modernatx Inc |
Vaccins à arn contre le virus zika
|
|
CA3080592A1
(en)
|
2017-10-31 |
2019-05-09 |
Modernatx, Inc. |
Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
|
|
US20190192646A1
(en)
|
2017-11-03 |
2019-06-27 |
Modernatx, Inc. |
Salmonella vaccines
|
|
CA3083102A1
(en)
|
2017-11-21 |
2019-05-31 |
Modernatx, Inc. |
Epstein-barr virus vaccines
|
|
WO2019148101A1
(en)
|
2018-01-29 |
2019-08-01 |
Modernatx, Inc. |
Rsv rna vaccines
|
|
EP3813848A4
(en)
|
2018-06-27 |
2022-07-20 |
ModernaTX, Inc. |
EPITOPE SELECTION FOR PERSONALIZED CANCER VACCINE
|
|
AU2019338557A1
(en)
|
2018-09-13 |
2021-03-25 |
Modernatx, Inc. |
Modified mRNA for the treatment of progressive familial intrahepatic cholestasis disorders
|
|
WO2020061284A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
Peg lipids and uses thereof
|
|
EP3853202A1
(en)
|
2018-09-19 |
2021-07-28 |
ModernaTX, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
|
EP4509118A3
(en)
|
2018-09-19 |
2025-05-14 |
ModernaTX, Inc. |
High-purity peg lipids and uses thereof
|
|
US12090235B2
(en)
|
2018-09-20 |
2024-09-17 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
|
WO2020097291A1
(en)
|
2018-11-07 |
2020-05-14 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
JP7635131B2
(ja)
|
2019-01-31 |
2025-02-25 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の調製方法
|
|
US11351242B1
(en)
|
2019-02-12 |
2022-06-07 |
Modernatx, Inc. |
HMPV/hPIV3 mRNA vaccine composition
|
|
CA3130888A1
(en)
|
2019-02-20 |
2020-08-27 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
|
CN113874502A
(zh)
|
2019-03-11 |
2021-12-31 |
摩登纳特斯有限公司 |
补料分批体外转录方法
|
|
US12070495B2
(en)
|
2019-03-15 |
2024-08-27 |
Modernatx, Inc. |
HIV RNA vaccines
|
|
CA3142352A1
(en)
|
2019-05-31 |
2020-12-03 |
Modernatx, Inc. |
Expanded t cell assay
|
|
JP2022544416A
(ja)
|
2019-08-14 |
2022-10-18 |
モデルナティエックス インコーポレイテッド |
ｉｎ ｖｉｔｒｏ転写の下流生成物を精製するプロセス
|
|
JP2022547313A
(ja)
|
2019-09-11 |
2022-11-11 |
モデルナティエックス インコーポレイテッド |
ヒトサイトメガロウイルスワクチン
|
|
BR112022004759A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
|
|
JP2022548957A
(ja)
|
2019-09-19 |
2022-11-22 |
モデルナティエックス インコーポレイテッド |
キャップガイド及びｒｎａマッピングのためのその使用方法
|
|
WO2021142306A1
(en)
|
2020-01-10 |
2021-07-15 |
Modernatx, Inc. |
Variational autoencoder for biological sequence generation
|
|
US20210228707A1
(en)
|
2020-01-28 |
2021-07-29 |
Modernatx, Inc. |
Coronavirus rna vaccines
|
|
JP2023513073A
(ja)
|
2020-01-30 |
2023-03-30 |
モデルナティエックス インコーポレイテッド |
呼吸器系ウイルス免疫化組成物
|
|
EP4096644A1
(en)
|
2020-01-31 |
2022-12-07 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
|
KR20220140528A
(ko)
|
2020-02-07 |
2022-10-18 |
모더나티엑스, 인크. |
Sars-cov-2 mrna 도메인 백신
|
|
WO2021211343A1
(en)
|
2020-04-13 |
2021-10-21 |
Modernatx, Inc. |
Zika virus mrna vaccines
|
|
WO2021222304A1
(en)
|
2020-04-27 |
2021-11-04 |
Modernatx, Inc. |
Sars-cov-2 rna vaccines
|
|
US20230142529A1
(en)
|
2020-05-15 |
2023-05-11 |
Modernatx, Inc. |
Rna formulations for high volume distribution
|
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
|
WO2021237084A1
(en)
|
2020-05-21 |
2021-11-25 |
Modernatx, Inc. |
Methylene blue stabilized mrna compositions
|
|
CA3185855A1
(en)
|
2020-06-05 |
2021-12-09 |
Modernatx, Inc. |
Bacterial strains for dna production
|
|
IL300111A
(en)
|
2020-08-06 |
2023-03-01 |
Modernatx Inc |
The vehicles for the transfer of cargo molecules to the airway epithelium
|
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
|
US20230355743A1
(en)
|
2020-09-25 |
2023-11-09 |
Modernatx, Inc. |
Multi-proline-substituted coronavirus spike protein vaccines
|
|
US12329811B2
(en)
|
2021-01-11 |
2025-06-17 |
Modernatx, Inc. |
Seasonal RNA influenza virus vaccines
|
|
AU2022208057A1
(en)
|
2021-01-15 |
2023-08-03 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
CA3208303A1
(en)
|
2021-01-15 |
2022-07-21 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines
|
|
CN117355329A
(zh)
|
2021-03-05 |
2024-01-05 |
摩登纳特斯有限公司 |
Vlp肠道病毒疫苗
|
|
WO2022197624A1
(en)
|
2021-03-15 |
2022-09-22 |
Modernatx, Inc. |
Therapeutic use of sars-cov-2 mrna domain vaccines
|
|
JP2024511179A
(ja)
|
2021-03-26 |
2024-03-12 |
モデルナティエックス インコーポレイテッド |
百日咳ワクチン
|
|
WO2022212442A1
(en)
|
2021-03-31 |
2022-10-06 |
Modernatx, Inc. |
Synthesis of trinucleotide and tetranucleotide caps for mrna production
|
|
AU2022249357A1
(en)
|
2021-04-01 |
2023-10-12 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
|
EP4314046A4
(en)
|
2021-04-01 |
2025-03-19 |
ModernaTX, Inc. |
Mucosal expression of antibody structures and isotypes by mRNA
|
|
CN117529335A
(zh)
|
2021-04-13 |
2024-02-06 |
摩登纳特斯有限公司 |
爱泼斯坦-巴尔病毒mrna疫苗
|
|
AU2022258335A1
(en)
|
2021-04-13 |
2023-11-23 |
Modernatx, Inc. |
Respiratory virus combination vaccines
|
|
WO2022221336A1
(en)
|
2021-04-13 |
2022-10-20 |
Modernatx, Inc. |
Respiratory syncytial virus mrna vaccines
|
|
WO2022221440A1
(en)
|
2021-04-14 |
2022-10-20 |
Modernatx, Inc. |
Influenza-coronavirus combination vaccines
|
|
EP4326241A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
|
US20220370616A1
(en)
|
2021-04-23 |
2022-11-24 |
Modernatx, Inc. |
Stabilized formulations
|
|
WO2022232585A1
(en)
|
2021-04-29 |
2022-11-03 |
Modernatx, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
|
US20220363937A1
(en)
|
2021-05-14 |
2022-11-17 |
Armstrong World Industries, Inc. |
Stabilization of antimicrobial coatings
|
|
WO2022245888A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Seasonal flu rna vaccines and methods of use
|
|
US20240285754A1
(en)
|
2021-06-14 |
2024-08-29 |
Modernatx, Inc. |
Mrna vaccines encoding flexible coronavirus spike proteins
|
|
WO2022266012A1
(en)
|
2021-06-14 |
2022-12-22 |
Modernatx, Inc. |
Coronavirus glycosylation variant vaccines
|
|
US20240218353A1
(en)
|
2021-06-17 |
2024-07-04 |
Modernatx, Inc. |
Alternative rna purification strategies
|
|
US20240382581A1
(en)
|
2021-07-09 |
2024-11-21 |
Modernatx, Inc. |
Pan-human coronavirus vaccines
|
|
WO2023283645A1
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus domain vaccines
|
|
WO2023283642A2
(en)
|
2021-07-09 |
2023-01-12 |
Modernatx, Inc. |
Pan-human coronavirus concatemeric vaccines
|
|
WO2023014649A1
(en)
|
2021-08-02 |
2023-02-09 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
|
WO2023018773A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
|
US20240368580A1
(en)
|
2021-08-13 |
2024-11-07 |
Modernatx, Inc. |
Multicolumn chromatography mrna purification
|
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
|
JP2024540917A
(ja)
|
2021-10-18 |
2024-11-06 |
モデルナティエックス インコーポレイテッド |
組み換えタンパク質生産のためのカスタム株
|
|
US20250011798A1
(en)
|
2021-10-18 |
2025-01-09 |
Modernatx, Inc. |
Markerless dna production
|
|
EP4419082A1
(en)
|
2021-10-20 |
2024-08-28 |
ModernaTX, Inc. |
Drug product surrogate solutions
|
|
WO2023076658A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Mass spectrometry of mrna
|
|
EP4426855A1
(en)
|
2021-11-05 |
2024-09-11 |
ModernaTX, Inc. |
Methods of purifying dna for gene synthesis
|
|
WO2023092069A1
(en)
|
2021-11-18 |
2023-05-25 |
Modernatx, Inc. |
Sars-cov-2 mrna domain vaccines and methods of use
|
|
US20250360194A1
(en)
|
2021-12-08 |
2025-11-27 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
|
EP4448777A1
(en)
|
2021-12-15 |
2024-10-23 |
ModernaTX, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
|
US20250084397A1
(en)
|
2022-01-04 |
2025-03-13 |
Modernatx, Inc. |
Methods of purifying dna for gene synthesis
|
|
US20250115897A1
(en)
|
2022-01-14 |
2025-04-10 |
Modernatx, Inc. |
In vitro transcription dna purification and recycling
|
|
CN118647718A
(zh)
|
2022-02-03 |
2024-09-13 |
摩登纳特斯有限公司 |
用于mRNA纯化的连续沉淀
|
|
TW202345863A
(zh)
|
2022-02-09 |
2023-12-01 |
美商現代公司 |
黏膜投與方法及調配物
|
|
WO2023196914A1
(en)
|
2022-04-08 |
2023-10-12 |
Modernatx, Inc. |
Influenza nucleic acid compositions and uses thereof
|
|
US20250250614A1
(en)
|
2022-04-11 |
2025-08-07 |
c/o ModernaTX, Inc. |
Detection of mrna purity in a mixture
|
|
WO2023201294A1
(en)
|
2022-04-14 |
2023-10-19 |
Modernatx, Inc. |
Rna polymerase variants
|
|
EP4508069A1
(en)
|
2022-04-15 |
2025-02-19 |
ModernaTX, Inc. |
Ribosomal engagement potency assay
|
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
|
WO2023225524A1
(en)
|
2022-05-17 |
2023-11-23 |
Modernatx, Inc. |
Preparation of highly concentrated mrna
|
|
WO2023250119A1
(en)
|
2022-06-24 |
2023-12-28 |
Modernatx, Inc. |
Methods of producing rna
|
|
US20250388963A1
(en)
|
2022-07-06 |
2025-12-25 |
Modernatx, Inc. |
Primer design for cell-free dna production
|
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
|
US20260035685A1
(en)
|
2022-07-28 |
2026-02-05 |
Modernatx, Inc. |
Methods of rna purification
|
|
WO2024030369A1
(en)
|
2022-08-01 |
2024-02-08 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
|
EP4612301A1
(en)
|
2022-11-03 |
2025-09-10 |
ModernaTX, Inc. |
Chemical stability of mrna
|
|
WO2024123978A1
(en)
|
2022-12-08 |
2024-06-13 |
Modernatx, Inc. |
Ionizable lipids with malonate tails
|
|
WO2024151811A1
(en)
|
2023-01-11 |
2024-07-18 |
Modernatx, Inc. |
Personalized cancer vaccines
|
|
WO2024163465A1
(en)
|
2023-01-30 |
2024-08-08 |
Modernatx, Inc. |
Epstein-barr virus mrna vaccines
|